ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Jardiance becomes first SGLT2 inhibitor to show benefit in HFpEF
July 07, 2021Eli Lilly and Boehringer Ingelheim have revealed positive results from a Phase III study of its SGLT2 inhibitor Jardiance in patients with heart failure with preserved ejection fraction (HFpEF). -
Daewoong Pharmaceutical announces Korea's first-ever SGLT2 inhibitor for diabetes treatment
September 30, 2020Daewoong Pharmaceutical (Daewoong) (CEO Sengho Jeon) announced the result of its phase 2 clinical trial on enavogliflozin, SGLT2 inhibitor for diabetes currently in the process of development, for the first time at the ...
Pharma Sources Insight January 2025
